Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 20, 2019 16:05 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Appointment of Scott D. Myers to Board of Directors

WATERTOWN, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
June 12, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Presents Full Data from Phase 2 Trial of SEL-212 for Chronic Refractory Gout at EULAR 2019

WATERTOWN, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
May 30, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Jefferies Healthcare Conference on June 06, 2019

WATERTOWN, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
May 09, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update

- Patient enrollment ongoing in COMPARE trial evaluating efficacy and safety of SEL-212 vs. KRYSTEXXA® in patients with chronic refractory gout; interim data expected in 4Q19 - - Preclinical data...
May 02, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Announce Date of First Quarter 2019 Financial Results Conference Call

WATERTOWN, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
April 16, 2019 16:05 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting

WATERTOWN, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
April 02, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Needham & Company 18th Annual Healthcare Conference April 9, 2019

WATERTOWN, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
March 29, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team

-First patient enrolled in COMPARE trial evaluating efficacy and safety of SEL-212 v. KRYSTEXXA® in patients with chronic refractory gout-Strengthened management and clinical teams with the...
March 26, 2019 16:05 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces New Employment Inducement Grant

WATERTOWN, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
March 15, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update

Phase 2 head-to-head (COMPARE) clinical trial of SEL-212 vs. KRYSTEXXA® to begin in 1Q19, interim six-month data expected in 4Q19Collaboration with CureCN projected to dose first patient with...